{"doi":"10.1002/cncr.70211","title":"Examining trends in lung cancer screening over 10 years: Eligibility, participation, cancer detection, and quality implications","abstract":"BACKGROUND: More than a decade ago, the National Lung Screening Trial led to the recommendation of low-dose computed tomography (CT) for lung cancer screening (LCS). However, few studies have explored how program changes and external factors affect patient outcomes. METHODS: This retrospective study included LCS-eligible individuals from Kaiser Permanente Colorado between May 1, 2014, and December 31, 2024. Rates and proportions of LCS orders, completions, adherence to recommended follow-up after baseline screening, and lung cancer yield were calculated. Multivariable log-binomial regression models estimated the factors associated with baseline LCS completion. RESULTS: Of 23,602 LCS-eligible individuals, 13,576 (58%) received a baseline LCS order and 8621 (37% of eligible; 64% of orders) completed screening. LCS completion was more likely among Asian/Native Hawaiian/Pacific Islander or Black races, and individuals who formerly smoked, had a 20- to 29-pack-year smoking history, >1 specialty care visit, a family history of lung cancer, or a greater comorbidity burden. Overall adherence to recommended follow-up was 62%; patients with a Lung CT Screening Reporting and Data System (Lung-RADS) score of 4B or 4X had the highest adherence at 88%. LCS yielded 424 cases of lung cancer (5% of screened), with 68% at stage I, II, or IIIA. Cumulative incidence among those with a positive Lung-RADS score was 20% at 10 years. Secular changes in LCS outcomes correlated with changes to LCS navigation processes, technology, and the coronavirus disease 2019 pandemic. CONCLUSIONS: This evaluation of a decade of robust LCS data within a community setting highlights the need for established national quality metrics that incentivize health systems to conduct ongoing program monitoring, evaluation, and adaptation to optimize screening benefits.","journal":"Cancer","year":2025,"id":585541,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.888,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":484990,"name":"Nikki M. Carroll","orcid":"0000-0003-1905-3287","position":1,"is_corresponding":false},{"id":1305888,"name":"Kris Wain","orcid":"0000-0003-0260-1523","position":2,"is_corresponding":false},{"id":889079,"name":"Brian Hixon","orcid":"0000-0001-6825-7409","position":3,"is_corresponding":false},{"id":583210,"name":"Roger Y. Kim","orcid":"0000-0002-8262-484X","position":4,"is_corresponding":false},{"id":1287331,"name":"Mahesh Maiyani","orcid":null,"position":5,"is_corresponding":false},{"id":485792,"name":"Julie S. Steiner","orcid":null,"position":6,"is_corresponding":false},{"id":360751,"name":"Debra P. Ritzwoller","orcid":"0000-0001-7116-8458","position":0,"is_corresponding":true}],"reference_count":33,"raw_metadata":null,"created_at":"2026-07-19T02:59:20.067334Z","pmid":"41405566","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}